One of the world’s leading specialists in mRNA therapeutics has partnered with California’s CytomX Therapeutics to create novel cancer meds. 6 January 2023
A report from industry commentator GlobalData highlights the potential for cell therapies to transform the treatment of multiple sclerosis (MS). 5 January 2023
CAR-T therapy company Allogene Therapeutics has swiftly named its replacement for executive vice president of research and development Rafael Amado, who has res 3 January 2023
Bayer subsidiary Asklepios BioPharmaceutical (AskBio) has drawn attention to the role of its own adeno-associated virus technology in all US Food and Drug Admin 22 December 2022
US clinical-stage biotech Magenta Therapeutics has halted dosing in one of the groups taking part in a Phase I/II study of cancer candidate MGTA-117. 21 December 2022
Replay, a genome writing company reprogramming biology by writing and delivering big DNA, has announced the launch of Kaleibe, a herpes simplex virus (HSV) gene 14 December 2022
UK biotech Autolus Therapeutics has announced that the pivotal Phase II FELIX trial of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult acut 9 December 2022
Anjarium Biosciences, a Swiss biotech focused on creating and delivering a new class of non-viral gene therapies, has announced the appointment of Otmane Boussi 8 December 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.